A STUDY ON THE CLINICAL CHARACTERISTICS OF MALIGNANT OVARIAN MUCINOUS TUMORS
Main Article Content
Abstract
Background: Mucinous ovarian tumors are the second most common subtype of epithelial ovarian tumors, accounting for approximately 10–15% of all cases. The prognostic factors associated with recurrence in malignant mucinous ovarian tumors remain controversial due to limited studies and inconsistent findings.Objective: To describe the clinical characteristics of malignant mucinous ovarian tumors treated at Tu Du Hospital. To determine the recurrence rate and identify factors associated with recurrence in these tumors. Methods: A retrospective cohort study was conducted. Results: With a follow-up period of 60 months, the overall recurrence rate of malignant mucinous ovarian tumors was 6.45% (95% CI: 3.89–11.66). Factors significantly associated with increased recurrence risk included: Tumor rupture during surgery, which was associated with a 4.70-fold higher risk of recurrence (95% CI: 1.06–20.81; p < 0.05); Advanced FIGO stage (III or higher), which increased the risk of recurrence by 7.91 times compared to stage I (95% CI: 1.56–40.02; p < 0.05). Interestingly, for each 1 cm increase in tumor size, the risk of recurrence decreased by 67% (HR = 0.33; 95% CI: 0.12–0.93; p < 0.05). Conclusion: Patients with malignant mucinous ovarian tumors should be carefully counseled and closely monitored, especially those with intraoperative tumor rupture or advanced-stage disease (FIGO stage III or higher), as they present a higher risk of recurrence. Notably, smaller tumor size was paradoxically associated with increased risk of recurrence.
Article Details
Keywords
u tuyến dịch nhầy buồng trứng ác tính, yếu tố tiên lượng tái phát
References
2. Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11-27. doi: 10.1016/j.humpath.2018.06.018.
3. C Simon Herrington & Editorial Board WCOT. WHO Classification of Tumours Female Genital Tumours. 5th ed. International Agency for Research on Cancer2020. p. 48-53.
4. Gupta S, Kalwaniya D, Shamsunder S. A comprehensive review of mucinous ovarian cancer: insights into epidemiology, risk factors, histological characteristics, and clinical outcomes. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2024;13: 474-82. doi: 10.18203/2320-1770. ijrcog20240158.
5. Hollis RL, Stillie LJ, Hopkins S, Bartos C, Churchman M, Rye T, et al. Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma. Cancers. 2021;13(22). doi: 10.3390/cancers13225839.
6. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16(6):389. doi: 10.1007/s11912-014-0389-x.
7. Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Nagasaka T, Kikkawa F. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study. European journal of obstetrics, gynecology, and reproductive biology. 2019;234:131-6. doi: 10.1016/j.ejogrb.2019.01.009.
8. Sun L, Li N, Song Y, Wang G, Zhao Z, Wu L. Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2018;28(9): 1643-9. doi: 10.1097/igc. 0000000000001362.
9. Kumari S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecologic oncology reports. 2021;36: 100756. doi: 10.1016/j.gore.2021. 100756.
10. Vo TM, Duong KA, Tran LT, Bui TC. Recurrence rate and associated factors of borderline ovarian tumors in the south of Vietnam. The journal of obstetrics and gynaecology research. 2019;45(10):2055-61. doi: 10.1111/jog.14072.